Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss DOI Creative Commons
Allison B. Reiss,

Shelly Gulkarov,

Raymond Lau

et al.

Biomolecules, Journal Year: 2025, Volume and Issue: 15(3), P. 408 - 408

Published: March 13, 2025

Worldwide, nearly 40% of adults are overweight and 13% obese. Health consequences excess weight include cardiovascular diseases, type 2 diabetes, dyslipidemia, increased mortality. Treating obesity is challenging calorie restriction often leads to rebound gain. Treatments such as bariatric surgery create hesitancy among patients due their invasiveness. GLP-1 medications have revolutionized loss can reduce body in obese by between 15% 25% on average after about 1 year. Their mode action mimic the endogenous GLP-1, an intestinal hormone that regulates glucose metabolism satiety. However, drugs carry known risks and, since use for recent, may unforeseen well. They a boxed warning people with personal or family history medullary thyroid carcinoma multiple endocrine neoplasia syndrome 2. Gastrointestinal adverse events (nausea, vomiting, diarrhea) fairly common while pancreatitis obstruction rarer. There be lean mass well premature facial aging. A significant disadvantage using these high rate regain when they discontinued. Achieving success pharmacologic treatment then weaning avoid future negative effects would ideal.

Language: Английский

Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss DOI Creative Commons
Allison B. Reiss,

Shelly Gulkarov,

Raymond Lau

et al.

Biomolecules, Journal Year: 2025, Volume and Issue: 15(3), P. 408 - 408

Published: March 13, 2025

Worldwide, nearly 40% of adults are overweight and 13% obese. Health consequences excess weight include cardiovascular diseases, type 2 diabetes, dyslipidemia, increased mortality. Treating obesity is challenging calorie restriction often leads to rebound gain. Treatments such as bariatric surgery create hesitancy among patients due their invasiveness. GLP-1 medications have revolutionized loss can reduce body in obese by between 15% 25% on average after about 1 year. Their mode action mimic the endogenous GLP-1, an intestinal hormone that regulates glucose metabolism satiety. However, drugs carry known risks and, since use for recent, may unforeseen well. They a boxed warning people with personal or family history medullary thyroid carcinoma multiple endocrine neoplasia syndrome 2. Gastrointestinal adverse events (nausea, vomiting, diarrhea) fairly common while pancreatitis obstruction rarer. There be lean mass well premature facial aging. A significant disadvantage using these high rate regain when they discontinued. Achieving success pharmacologic treatment then weaning avoid future negative effects would ideal.

Language: Английский

Citations

0